Emerging Therapeutic Treatments for Multidrug-Resistant Bacteria: A Review

The rapid rise of multidrug-resistant (MDR) bacteria poses a severe global health threat, rendering many conventional antibiotics ineffective and contributing to increased morbidity, mortality, and healthcare costs. In response to this escalating crisis, novel antimicrobial strategies are being explored, including bacteriophage therapy, CRISPR-Cas systems, and nanoparticle-based therapeutics. This review examines these innovative approaches' mechanisms, clinical progress, and limitations in combating MDR pathogens, particularly the WHO-prioritized ESKAPE group. Bacteriophages offer strain-specific bacterial killing with minimal off-target effects, but regulatory uncertainty, immune responses, and narrow host ranges hinder their use. CRISPR-Cas systems provide precise gene-editing capabilities to eliminate resistance genes or target specific bacterial strains, though concerns about off-target effects, delivery systems, and biosafety remain unresolved. Nanoparticles, including silver and gold NPs, and nano-drug delivery systems exhibit broad-spectrum antimicrobial properties and targeted delivery potential but raise cytotoxicity, standardization, and long-term safety issues. Despite their promise, each strategy faces critical challenges that must be addressed before clinical translation is viable. Integrating these therapies, alongside continued research, ethical oversight, and global collaboration, may offer a sustainable and adaptable solution to the growing burden of antimicrobial resistance.